A Louisiana federal judge largely rejected Novo Nordisks bid to dismiss the lawsuit, allowing the case to move forward, particularly on claims related to failure to warn about the risk of gastroparesis
For many people, the investment pays for itself through reduced medical costs and improved quality of life
S., et al., Clinical Consequences of Delayed Gastric Emptying With GLP1 Receptor Agonists and Tirzepatide, Journal of Clinical Endocrinology & Metabolism 110 (2024): 115, 10.1210/clinem/dgae719
The likelihood in humans is unclear, but anyone with a personal or family history of certain thyroid cancers should not use Wegovy
When appropriate, medication may be considered as one part of a broader medical weight loss strategy